ArticleJAMA surgery2022
Comparison of Hepatic Arterial Infusion Pump Chemotherapy vs Resection for Patients With Multifocal Intrahepatic Cholangiocarcinoma.
Article in JAMA surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06739252 (Perioperative Treatment of High-risk Resectable Cholangiocarcinoma With Hepatic Arterial Infusion Chemotherapy), which is not on this map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Perioperative Treatment of High-risk Resectable Cholangiocarcinoma With Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Atezo/Bevacizumab: a Multicenter Phase II Study (NeoBrave CCA)
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer.ESMO open · 2024Guideline
- Prolonged intratumoral treatment with TLR7/8 agonist R848 regulates the tumor immune microenvironment resulting in enhanced antitumor activity.Cancer biology & therapy · 2026Article
- To Resect or Not to Resect, That is the Question: Neoadjuvant Therapy as the Necessary Gatekeeper for Surgical Treatment in High-Risk Intrahepatic Cholangiocarcinoma.Annals of surgical oncology · 2026Article
- Eligibility for Liver Transplantation in Patients with Intrahepatic Cholangiocarcinoma.Annals of surgical oncology · 2026Article
- Association between primary tumor resection and survival in metastatic intrahepatic cholangiocarcinoma: a retrospective cohort study based on the SEER database.Journal of gastrointestinal oncology · 2026Article
- Outcomes After Resection for Multiple Intrahepatic Cholangiocarcinoma-A National Population-Based Study.Annals of surgical oncology · 2026Article
- Prognostic implications of tumour number in intrahepatic cholangiocarcinoma.JHEP reports : innovation in hepatology · 2026Article
- Hepatic Artery Infusion Chemotherapy for Cholangiocarcinoma in 2025.Liver cancer · 2026Review
- Outcomes of First Versus Second-Line Hepatic Artery Infusion Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma.Annals of surgical oncology · 2026Article
- Recent advances in molecular classification and multimodal treatment of intrahepatic cholangiocarcinoma.World journal of surgical oncology · 2026Review
- Cholangiocarcinoma 2026: status quo, unmet needs and priorities.Nature reviews. Gastroenterology & hepatology · 2026Review
- Oncological Resectability Criteria for Intrahepatic Cholangiocarcinoma: A Preoperative Framework for Multidisciplinary Management.Annals of surgical oncology · 2025Article
- Article
- Hepatic arterial infusion chemotherapy versus systemic chemotherapy in unresectable intrahepatic cholangiocarcinoma: a propensity score-matched analysis of efficacy and safety.Quantitative imaging in medicine and surgery · 2025Article
- Conversion treatment for advanced intrahepatic cholangiocarcinoma: Opportunities and challenges.World journal of gastroenterology · 2025Review
- Efficacy and safety of arterial FOLFOX chemotherapy plus anti-PD-(L)1 immunotherapy as a first-line treatment for unresectable intrahepatic cholangiocarcinoma: a propensity score matching analysis.Journal of gastrointestinal oncology · 2025Article
- Has Management of Intrahepatic Cholangiocarcinoma Evolved with the Evidence? Trends and Practice Patterns from the National Cancer Database.Annals of surgical oncology · 2024Article
- Hepatic Artery Infusion Chemotherapy for Primary and Secondary Malignancies of the Liver: State of the Art and Current High-Level Evidence.Pharmacology · 2024Review
- Clinical management of intrahepatic cholangiocarcinoma: surgical approaches and systemic therapies.Frontiers in oncology · 2024Review
- Techniques and status of hepatic arterial infusion chemotherapy for primary hepatobiliary cancers.Therapeutic advances in medical oncology · 2024Review
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
25 authors at 14 institutions in 7 countries.
Funding
Abstract
Importance: Intrahepatic cholangiocarcinoma (iCCA) is often multifocal (ie, satellites or intrahepatic metastases) at presentation. Objective: To compare the overall survival (OS) of patients with multifocal iCCA after hepatic arterial infusion pump (HAIP) floxuridine chemotherapy vs resection. Design, Setting, and Participants: In this cohort study, patients with histologically confirmed, multifocal iCCA were eligible. The HAIP group consisted of consecutive patients from a single center who underwent HAIP floxuridine chemotherapy for unresectable multifocal iCCA between January 1, 2001, and December 31, 2018. The resection group consisted of consecutive patients from 12 centers who underwent a curative-intent resection for multifocal iCCA between January 1, 1990, and December 31, 2017. Resectable metastatic disease to regional lymph nodes and previous systemic therapy were permitted. Patients with distant metastatic disease (ie, stage IV), those who underwent resection before starting HAIP floxuridine chemotherapy, and those who received a liver transplant were excluded. Data were analyzed on September 1, 2021. Main Outcomes and Measures: Overall survival in the 2 treatment groups was compared using the Kaplan-Meier method and log-rank test. Results: A total of 319 patients with multifocal iCCA were included: 141 in the HAIP group (median [IQR] age, 62 [53-70] years; 79 [56.0%] women) and 178 in the resection group (median [IQR] age, 60 [50-69] years; 91 [51.1%] men). The HAIP group was characterized by a higher percentage of bilobar disease (88.0% [n = 124] vs 34.3% [n = 61]), larger tumors (median, 8.4 cm vs 7.0 cm), and a higher proportion of patients with 4 or more lesions (66.7% [94] vs 24.2% [43]). Postoperative mortality after 30 days was 0.8% (95% CI, 0.0%-2.1%) in the HAIP group vs 6.2% (95% CI, 2.3%-9.7%) in the resection group (P = .01). The median OS for HAIP was 20.3 months vs 18.9 months for resection (P = .32). Five-year OS in patients with 2 or 3 lesions was 23.7% (95% CI, 12.3%-45.7%) in the HAIP group vs 25.7% (95% CI, 17.9%-37.0%) in the resection group. Five-year OS in patients with 4 or more lesions was 5.0% (95% CI, 1.7%-14.3%) in the HAIP group vs 6.8% (95% CI, 1.8%-25.3%) in the resection group. After adjustment for tumor diameter, number of tumors, and lymph node metastases, the hazard ratio of HAIP vs resection was 0.75 (95% CI, 0.55-1.03; P = .07). Conclusions and Relevance: This cohort study found that patients with multifocal iCCA had similar OS after HAIP floxuridine chemotherapy vs resection. Resection of multifocal intrahepatic cholangiocarcinoma needs to be considered carefully given the complication rate of major liver resection; HAIP floxuridine chemotherapy may be an effective alternative option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.